Results 71 to 80 of about 13,568,693 (193)

N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo

, 2020
N,N-dimethyltryptamine (DMT) is a component of the ayahuasca brew traditionally used for ritual and therapeutic purposes across several South American countries. Here, we have examined, in vitro and vivo, the potential neurogenic effect of DMT.
Perez-Castillo, Ana, Alonso Gil, Sandra, Calleja Conde, Javier, Sanz SanCristobal, Marina, Lopez-Moreno, Jose A, Riba, Jordi, López Moreno, José Antonio, Alonso-Gil, Sandra, Morales-Garcia, Jose A., Morales García, José Ángel, Calleja-Conde, Javier, Morales-Garcia, Jose A, Lopez-Moreno, Jose A., Pérez Castillo, Ana, Sanz-SanCristobal, Marina   +14 more
core   +1 more source

Pharmacokinetics and pharmacodynamics of intravenous and oral (S)‐ketamine: Investigating metabolite contribution to subjective effects

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2260-2271, July 2026.
Aims Oral administration of (S)‐ketamine for treatment‐resistant depression (TRD), as alternative to the registered intranasal or off‐label intravenous administrations, has high potential. However, it is characterized by an extensive first‐pass metabolism, resulting in low (S)‐ketamine exposure and high levels of active metabolites, including (S ...
Marije E. Otto, Gabriël E. Jacobs, Joost C. van Mechelen, Laura G. J. M. Borghans, Johan G. C. van Hasselt, Linda B. S. Aulin   +5 more
wiley   +1 more source

A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience

Frontiers in Pharmacology, 2016
The state of consciousness induced by N,N-dimethyltryptamine (DMT) is one of the most extraordinary of any naturally-occurring psychedelic substance.
Andrew Robert Gallimore, Rick Strassman
doaj   +1 more source

Acute effects of intravenous DMT in a randomized placebo-controlled study in healthy participants

Translational Psychiatry, 2023
N,N-dimethyltryptamine (DMT) is distinct among classic serotonergic psychedelics because of its short-lasting effects when administered intravenously. Despite growing interest in the experimental and therapeutic use of intravenous DMT, data are lacking ...
Severin B. Vogt, Laura Ley, Livio Erne, Isabelle Straumann, Anna M. Becker, Aaron Klaiber, Friederike Holze, Anja Vandersmissen, Lorenz Mueller, Urs Duthaler, Deborah Rudin, Dino Luethi, Nimmy Varghese, Anne Eckert, Matthias E. Liechti   +14 more
doaj   +1 more source

Changes over time in hallucinogen‐related emergency department visits in Ontario, Canada

Addiction, Volume 121, Issue 7, Page 1781-1793, July 2026.
Abstract Background and aims Recent increasing interest in hallucinogens has underscored the critical gaps in our understanding of their adverse health effects and healthcare usage over time. The current study aimed to examine changes in emergency department (ED) visit rates involving hallucinogens, clinical outcomes of visits and the characteristics ...
Daniel T. Myran, Rachael MacDonald‐Spracklin, Alexander R. Levesque, Michael Pugliese, Jess G. Fiedorowicz, André J. McDonald, Joshua D. Rosenblat, Ian Colman, Josephine Zein, Marco Solmi   +9 more
wiley   +1 more source

Preclinical models for evaluating psychedelics in the treatment of major depressive disorder

British Journal of Pharmacology, Volume 183, Issue 14, Page 3970-3991, July 2026.
Psychedelic drugs have seen a resurgence in interest as a next generation of psychiatric medicines with potential as rapid‐acting antidepressants (RAADs). Despite promising early clinical trials, the mechanisms which underlie the effects of psychedelics are poorly understood.
Laith Alexander, Dasha Anderson, Luke Baxter, Matthew Claydon, James Rucker, Emma S. J. Robinson   +5 more
wiley   +1 more source

Complex slow waves in the human brain under 5-MeO-DMT

Cell Reports
Summary: 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychedelic drug known for its uniquely profound effects on consciousness; however, it remains unknown how it affects the brain.
George Blackburne, Rosalind G. McAlpine, Marco Fabus, Alberto Liardi, Sunjeev K. Kamboj, Pedro A.M. Mediano, Jeremy I. Skipper   +6 more
doaj   +1 more source

Cancer Neuroscience: From Hallmark‐Enabling Biology to a Therapeutic Pillar

Advanced Oncology, Volume 1, Issue 1, December 2026.
Moran Amit
wiley   +1 more source

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology, Volume 183, Issue 14, Page 4048-4057, July 2026.
Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt, Peter Hunt, Anne Katrin Schlag, Paul Fitzgerald   +3 more
wiley   +1 more source

Psilocybin as a novel treatment for chronic pain

British Journal of Pharmacology, Volume 183, Issue 14, Page 3992-4005, July 2026.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey, Reena Lasrado, Maria Maiarú, Gary J. Stephens   +3 more
wiley   +1 more source